For the quarter ending 2026-03-31, ARQT had -$8,145K decrease in cash & cash equivalents over the period. $2,239K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss from operations | - | 18,387 | - | - |
| Interest income | - | 8,897 | - | - |
| Interest expense | - | 3,001 | - | - |
| Other income (expense), net | - | -6,418 | - | - |
| Provision for income taxes | - | 470 | - | - |
| Net loss | -11,295 | 17,395 | 7,410 | -15,886 |
| Stock-based compensation expense | 10,690 | 10,060 | 10,037 | 10,489 |
| Amortization of intangible assets | 562 | 563 | 562 | 563 |
| Non-cash interest expense | 461 | 461 | 449 | 431 |
| Net accretion on marketable securities | 182 | -11 | 551 | 695 |
| Other non-cash items, net | -214 | -21 | -283 | -348 |
| Accounts receivable, net | -1,852 | 31,113 | 8,429 | 21,272 |
| Inventory | 14,579 | 5 | 5,891 | -518 |
| Prepaid expenses and other current assets | 11,728 | 1,265 | 1,760 | -4,300 |
| Accounts payable | 5,613 | 6,731 | -9,288 | 554 |
| Accrued liabilities | 20,768 | 23,452 | 5,574 | 21,232 |
| Operating lease liabilities | -137 | -126 | -150 | -204 |
| Net cash provided by (used in) operating activities | 2,239 | 26,185 | -1,754 | 324 |
| Purchases of marketable securities | 62,153 | 89,180 | 68,544 | 33,152 |
| Proceeds from maturities of marketable securities | - | - | 43,297 | 60,653 |
| Milestone payment for intangible asset | - | 0 | 0 | 10,000 |
| Proceeds from maturities and sales of marketable securities | 50,821 | 227,419 | - | - |
| Purchases of property and equipment | 0 | 0 | 0 | 78 |
| Proceeds from issuance of common stock for espp | - | 1,057 | 0 | 1,319 |
| Net cash provided by (used in) investing activities | -11,332 | -34,179 | -25,247 | 17,423 |
| Proceeds from issuance of common stock, net of issuance costs | - | 0 | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | - | 0 | - | - |
| Repayment of long-term debt | - | 0 | - | - |
| Proceeds from issuance of shares under atm, net of issuance costs | - | 0 | - | - |
| Proceeds from issuance of common stock upon exercise of stock options | 1,067 | 2,665 | 1,476 | 61 |
| Net cash provided by financing activities | 1,067 | 3,722 | 1,476 | 1,380 |
| Effect of exchange rate changes on cash | -119 | 59 | -95 | 200 |
| Net decrease in cash, cash equivalents, and restricted cash | -8,145 | -4,213 | -25,620 | 19,327 |
| Cash, cash equivalents, and restricted cash at beginning of period | 43,215 | 47,428 | 73,048 | 53,721 |
| Cash, cash equivalents, and restricted cash at end of period | 35,070 | 43,215 | 47,428 | 73,048 |
Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT)